Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03369249
Other study ID # 7574
Secondary ID R01DA043122
Status Completed
Phase N/A
First received
Last updated
Start date December 9, 2017
Est. completion date December 1, 2022

Study information

Verified date December 2022
Source New York State Psychiatric Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study proposes to embed HIV testing outreach workers from a young adult focused medical and HIV treatment program into an alternative sentencing program to deliver a new service delivery model (Link2CARE) that integrates evidence-based protocols for justice-involved young adults to: a) promote HIV and STI testing, and HIV and SU risk screening, b) provide onsite intervention, and c) cross-system linkage to HIV, STI, and SU care. Phase 1 has already been completed. In phase 1, the intervention components were adapted for use among justice involved young adults and the resulting protocols were piloted with justice involved young adults, finalizing the resulting 4-session Link2CARE intervention. In phase 2, we will test Link2CARE among N=450 justice-involved young adults enrolled at the alternative sentencing program and conduct process evaluations with N=15 alternative sentencing program staff.


Recruitment information / eligibility

Status Completed
Enrollment 307
Est. completion date December 1, 2022
Est. primary completion date September 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Young Adults Inclusion Criteria: - Between 18-24 years of age - Currently enrolled at the alternative to sentencing program - Conversant in English - Engaged in any unprotected or vaginal sexual activity (in the past 12 months) Exclusion Criteria: - Cognitively unable to complete the interview - HIV positive Alternative to Sentencing Staff Inclusion Criteria: - Currently employed at the alternative to sentencing program - Between ages of 18-80 Exclusion Criteria: - None

Study Design


Intervention

Behavioral:
Link2CARE
The Link2CARE intervention consists of 4 sessions. Session 1 consists of a one-on-one meeting with a Health Coach, during which participants will be offered an oral rapid HIV test and STI test. Sessions 2, 3, and 4 are group-based. During these sessions, participants will engage in discussions and activities regarding sexual and substance use risk behaviors.

Locations

Country Name City State
United States Kings County Criminal Court Brooklyn New York

Sponsors (5)

Lead Sponsor Collaborator
New York State Psychiatric Institute Center for Court Innovation, Columbia University, National Institute on Drug Abuse (NIDA), The National Center on Addiction and Substance Abuse at Columbia University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of HIV+ Young Adults Referred to HIV Treatment measured by Health Coach report in the Health Coach logs and participant report in the "HIV Referral" section of the questionnaires at 3-, 6-, and 12-month follow-ups
Other Number of HIV+ Young Adults Attending at Least One Treatment Appointment measured by Health Coach report in the Health Coach logs and participant report in the "HIV Treatment" section of the questionnaires at 3-, 6-, and 12-month follow-ups
Other Number of Young Adults Behaviorally PrEP Eligible Referred to PrEP/Medical Care measured by Health Coach report in the Health Coach logs and participant report in the "PrEP Referral" section of the questionnaires at 3-, 6-, and 12-month follow-ups
Other Number of Young Adults Behaviorally PrEP Eligible Attending at Least One HIV Care Appointment measured by Health Coach report in the Health Coach logs and participant report in the "PrEP Uptake" section of the questionnaires at 3-, 6-, and 12-month follow-ups
Primary Total Number of Unprotected Anal and Vaginal Sex Occasions in Past 3 Months measured by participant report in the "Sexual Risk" section of the questionnaires at 12-month follow-up
Secondary Frequency of Young Adults Substance Use in Past 30 Days measured by participant report in the "Substance Use" section of the questionnaires at 3-, 6-, and 12-month follow-ups
Secondary Number of Young Adults Referred to Substance Use Treatment measured by Health Coach report in the Health Coach logs and participant report in the "Substance Use Referral" section of the questionnaires at 3-, 6-, and 12-month follow-ups
Secondary Number of Young Adults Attending Intake Plus One Treatment Session measured by Health Coach report in the Health Coach logs and participant report in the "Substance Use Treatment" section of the questionnaires at 3-, 6-, and 12-month follow-ups
Secondary Acceptance of STI Testing (Yes/no) measured by Health Coach report in the "Session 1 Sexual Risk" questionnaire at day 1 of enrollment
Secondary Any STI Testing measured by participant report in the "STI Testing" section of the questionnaires between 6- and 12-month follow-ups
Secondary Number of STI+ Young Adults Referred to STI Treatment measured by the Health Coach report in the Health Coach Logs and participant report in the "STI Referral" section of the questionnaires at 3-, 6-, and 12-month follow-ups
Secondary Number of STI+ Young Adults Attending 1 or More Treatment Appointments measured by Health Coach report in the Health Coach logs and participant report in the "STI Treatment" section of the questionnaires at 3-, 6-, and 12-month follow-ups
Secondary Acceptance of HIV Testing (Yes/no) measured by Health Coach report in the "Session 1 Sexual Risk" questionnaire at day 1 of enrollment
Secondary Any HIV Testing measured by participant report in the "HIV Testing" section of the questionnaires between 6-month and 12-month follow-ups
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2